Literature DB >> 9859967

Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial.

A R Sheon1, L Wagner, M J McElrath, M C Keefer, E Zimmerman, H Israel, D Berger, P Fast.   

Abstract

CONTEXT: Preventive HIV vaccines can temporarily cause uninfected individuals to have positive results on HIV testing. As preparations are underway to mount larger efficacy trials, the social risks of trial participation should be studied.
OBJECTIVE: To describe frequency of HIV testing and discrimination among participants in a preventive phase II HIV vaccine trial. PARTICIPANTS: 266 vaccine trial volunteers were eligible; 247 participated in a confidential survey.
RESULTS: 63 volunteers (26% of respondents) reported 185 HIV tests during the prior 12 to 24 months; most tests were for other research studies, health care, insurance, incarceration, or employment. Only 5 volunteers reported having positive HIV test results. Volunteers reported 99 adverse social incidents or problems, 53 of which were related to the trial. The most common type of event occurred when volunteers disclosed their trial participation and were mistakenly presumed to be infected with HIV. Few reported difficulty obtaining insurance, job loss, and inadvertent disclosure of their participation in the trial.
CONCLUSION: In this vaccine trial, few serious social harms were reported. Those who conduct HIV tests for insurance, employment, health care, or other reasons should be made aware that HIV vaccines can cause false-positive HIV test results. Those planning future trials must continue to provide needed support to volunteers. Social harms should be monitored with the same vigilance accorded to physical harms.

Entities:  

Keywords:  Biomedical and Behavioral Research; Empirical Approach

Mesh:

Substances:

Year:  1998        PMID: 9859967     DOI: 10.1097/00042560-199812150-00012

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  12 in total

Review 1.  Building and testing an effective HIV vaccine.

Authors:  J Kahn
Journal:  West J Med       Date:  1999 Nov-Dec

2.  Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes.

Authors:  Surender Khurana; James Needham; Susan Park; Bonnie Mathieson; Michael P Busch; George Nemo; Phillipe Nyambi; Susan Zolla-Pazner; Suman Laal; Joseph Mulenga; Elwyn Chomba; Eric Hunter; Susan Allen; James McIntyre; Indira Hewlett; Sherwin Lee; Shixing Tang; Elliot Cowan; Chris Beyrer; Marcus Altfeld; Xu G Yu; Anatole Tounkara; Ousmane Koita; Anatoli Kamali; Nga Nguyen; Barney S Graham; Deborah Todd; Peter Mugenyi; Omu Anzala; Eduard Sanders; Nzeera Ketter; Patricia Fast; Hana Golding
Journal:  J Acquir Immune Defic Syndr       Date:  2006-11-01       Impact factor: 3.731

3.  Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002.

Authors:  Gaston Djomand; Joanna Katzman; Dante di Tommaso; Michael G Hudgens; George W Counts; Beryl A Koblin; Patrick S Sullivan
Journal:  Public Health Rep       Date:  2005 Sep-Oct       Impact factor: 2.792

4.  Issues in women's participation in a phase III community HIV vaccine trial in Thailand.

Authors:  Jaranit Kaewkungwal; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Chirasak Khamboonruang; Prayura Kunasol; Pravan Suntharasamai; Swangjai Pungpak; Sirivan Vanijanonta; Valai Bussaratid; Wirach Maek-A-Nantawat; Jittima Dhitavat; Prasert Thongcharoen; Rungrawee Pawarana; Yupa Sabmee; Mike W Benenson; Patricia Morgan; Robert J O'Connell; Jerome Kim
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-25       Impact factor: 2.205

5.  Social Impacts Among Participants in HIV Vaccine Trial Network (HVTN) Preventive HIV Vaccine Trials.

Authors:  Michele P Andrasik; Fredericka Albertina Sesay; Abby Isaacs; Linda Oseso; Mary Allen
Journal:  J Acquir Immune Defic Syndr       Date:  2020-08-15       Impact factor: 3.731

6.  Engaging members of African American and Latino communities in preventive HIV vaccine trials.

Authors:  Magdalena E Sobieszczyk; Guozhen Xu; Krista Goodman; Debbie Lucy; Beryl A Koblin
Journal:  J Acquir Immune Defic Syndr       Date:  2009-06-01       Impact factor: 3.731

7.  Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies.

Authors:  Surender Khurana; James Needham; Bonnie Mathieson; Isaac R Rodriguez-Chavez; Andrew T Catanzaro; Robert T Bailer; Jerome Kim; Vicky Polonis; David A Cooper; Jan Guerin; Michael L Peterson; Marc Gurwith; Nga Nguyen; Barney S Graham; Hana Golding
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

8.  Exceptional Risk: Healthy Volunteers' Perceptions of HIV/AIDS Clinical Trials.

Authors:  Marci D Cottingham; Julianne M Kalbaugh; Teresa Swezey; Jill A Fisher
Journal:  J Acquir Immune Defic Syndr       Date:  2018-10-01       Impact factor: 3.731

9.  Social harms in female-initiated HIV prevention method research: state of the evidence.

Authors:  Elizabeth T Montgomery; Sarah T Roberts; Annalene Nel; Mariette Malherbe; Kristine Torjesen; Katherine Bunge; Devika Singh; Jared M Baeten; Jeanne Marrazzo; Z Mike Chirenje; Samuel Kabwigu; Richard Beigi; Sharon A Riddler; Zakir Gaffour; Krishnaveni Reddy; Leila E Mansoor; Gonasagrie Nair; Kusbashni Woeber; Jayajothi Moodley; Nitesha Jeenarain; Samantha Siva; Logashvari Naidoo; Vaneshree Govender; Thesla Palanee-Phillips
Journal:  AIDS       Date:  2019-11-15       Impact factor: 4.177

10.  "Research participants want to feel they are better off than they were before research was introduced to them": engaging cameroonian rural plantation populations in HIV research.

Authors:  Emmanuel Kiawi; Eleanor McLellan-Lemal; Jembia Mosoko; Kata Chillag; Pratima L Raghunathan
Journal:  BMC Int Health Hum Rights       Date:  2012-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.